Corsee D.  Sanders net worth and biography

Corsee Sanders Biography and Net Worth

Dr. Sanders has served as a member of the Ultragenyx board since June 2021. Most recently, she served as executive vice president of development operations at Juno Therapeutics and strategic advisor to the office of the Celgene chief medical officer, following Celgene’s acquisition of Juno. She also served as transition advisor to the clinical development team at Bristol Myers Squibb (BMS), which acquired Celgene. Prior to her role at BMS, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as senior vice president, global head of clinical operations and industry collaboration for six years.

Dr. Sanders currently serves as a member of the board of directors of several biotechnology companies including Beigene Ltd., Molecular Templates Inc., Legend Biotech Corporation and AltruBio Inc. (formerly AbGenomics Inc.). Dr. Sanders is an advisory committee member for the George Schultz Innovation Fund of the University of Chicago. She is also co-chair of the board of advisors and chair of the science and technology advisory committee for the Fred Hutchinson Cancer Research Center. Dr. Sanders graduated magna cum laude from the University of the Philippines where she earned a B.S. and M.S. in statistics. She also earned an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.

What is Corsee D. Sanders' net worth?

The estimated net worth of Corsee D. Sanders is at least $285,716.16 as of June 10th, 2024. Dr. Sanders owns 7,248 shares of Ultragenyx Pharmaceutical stock worth more than $285,716 as of June 24th. This net worth estimate does not reflect any other investments that Dr. Sanders may own. Learn More about Corsee D. Sanders' net worth.

How do I contact Corsee D. Sanders?

The corporate mailing address for Dr. Sanders and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Corsee D. Sanders' contact information.

Has Corsee D. Sanders been buying or selling shares of Ultragenyx Pharmaceutical?

Over the course of the past ninety days, Corsee D. Sanders has sold $71,390.70 of Ultragenyx Pharmaceutical stock. Most recently, Corazon (Corsee) D. Sanders sold 1,737 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.10, for a transaction totalling $71,390.70. Following the completion of the sale, the director now directly owns 7,248 shares of the company's stock, valued at $297,892.80. Learn More on Corsee D. Sanders' trading history.

Who are Ultragenyx Pharmaceutical's active insiders?

Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Mardi Dier (CFO), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.

Are insiders buying or selling shares of Ultragenyx Pharmaceutical?

During the last twelve months, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 141,108 shares worth more than $5,449,277.97. The most recent insider tranaction occured on June, 12th when EVP Karah Herdman Parschauer sold 9,806 shares worth more than $441,270.00. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.

Information on this page was last updated on 6/12/2024.

Corsee D. Sanders Insider Trading History at Ultragenyx Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2024Sell1,737$41.10$71,390.707,248View SEC Filing Icon  
6/30/2023Sell585$46.76$27,354.608,985View SEC Filing Icon  
6/8/2023Sell1,485$51.65$76,700.259,570View SEC Filing Icon  
See Full Table

Corsee D. Sanders Buying and Selling Activity at Ultragenyx Pharmaceutical

This chart shows Corazon (Corsee) D Sanders's buying and selling at Ultragenyx Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $39.42
Low: $39.13
High: $40.30

50 Day Range

MA: $41.55
Low: $37.42
High: $45.11

2 Week Range

Now: $39.42
Low: $31.52
High: $54.56


818,377 shs

Average Volume

805,408 shs

Market Capitalization

$3.28 billion

P/E Ratio


Dividend Yield